Elior

09/07/20 -"Taking into account the recent trading update of one of Elior's major rivals, we are convinced that the health crisis may not have such a severe impact in the near term and that a recovery may take ..."

PDF page sample
Pages
53
Language
English
Published on
09/07/20
Download
You may also be interested by these reports :
23/10/26
Evolution’s Q3’26 results showed signs of recovery, with revenue up 4% at constant currency and RNG outperforming. North America and Latin America ...
23/10/26
IHG keeps delivering solid results with a broad-based Q3 RevPAR beat, record development activity, and confidence in FY26 consensus. Beyond the beat, ...
23/10/26
Sodexo’s FY26 results came in ahead of company consensus and of our forecasts. Organic growth reached +2.0%, lifted by a stronger-than-expected Q4 at ...
23/10/26
Accor reported solid figures with group RevPAR up +4.9%, ahead of expectations. The beat was entirely price-driven and concentrated in Luxury & ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO